However, AD patients were selected by clinicians from a specialized memory center based on the cut-off value for CSF tau to Aβ42 ratio [41] ensuring a more reliable diagnosis based on fluid biomarkers [58]. The gene discussed is MAPT; the disease is Alzheimer disease.